Every year, an estimated $3 billion is spent on preventive health screenings in the United States that the evidence does not support. At the same time, millions of adults skip colorectal cancer screenings that could catch disease at a curable stage. The gap between what we over-test and what we under-use is one of the more practical problems in American health care — and understanding it can help you spend your time, money, and anxiety more wisely.

This is not an argument against preventive care. It is an argument for better preventive care: knowing which screenings have strong evidence behind them, which ones are more marketing than medicine, and how to talk to your doctor about the difference.

How recommendations actually get made

The United States Preventive Services Task Force (USPSTF) is an independent, volunteer panel of primary-care physicians, epidemiologists, and methodologists commissioned by the federal government to review evidence on preventive services. Their recommendations are graded A through D — and an I for insufficient evidence.

  • Grade A: High certainty that net benefit is substantial. Recommend the service.
  • Grade B: High or moderate certainty that net benefit is moderate to substantial. Recommend the service.
  • Grade C: At least moderate certainty that net benefit is small. Offer or provide the service for selected patients based on professional judgment.
  • Grade D: Moderate or high certainty that the service has no net benefit or that harms outweigh benefits. Discourage use.

This grading system matters for a practical reason: under the Affordable Care Act, insurers are required to cover A and B recommendations with no cost-sharing — no copay, no deductible — for the populations to which they apply. A Kaiser Family Foundation (KFF) analysis found that this provision covers more than two dozen preventive services for most privately insured Americans. If you are being charged a copay for an A-rated screening, it is worth calling your insurer.

The high-value screenings — evidence is solid

These are services where the USPSTF assigns an A or B rating, meaning the evidence of benefit is strong and the harms (false positives, unnecessary follow-up procedures, anxiety) are considered acceptable relative to the lives and complications prevented.

Colorectal cancer screening, starting at 45

Colorectal cancer is the second-leading cause of cancer death in the United States and one of the most preventable. The USPSTF gives colorectal cancer screening for adults ages 45 to 75 an A recommendation. Multiple modalities qualify — colonoscopy every 10 years, annual high-sensitivity stool tests, CT colonography every 5 years, among others. The choice depends on patient preference and risk factors; the key is completing the test, not which test you choose. The CDC reports that if everyone aged 45 to 75 were screened, roughly 60 percent of colorectal cancer deaths could be prevented.

Hypertension screening

High blood pressure affects roughly one in three American adults, causes no symptoms, and is a leading risk factor for heart attack, stroke, and kidney disease. The USPSTF recommends blood pressure screening for all adults 18 and older — an A recommendation. The test takes minutes and is genuinely one of the most cost-effective things a clinical encounter can do. The CDC estimates that hypertension contributes to nearly half a million American deaths per year, most of them preventable with treatment.

Cervical cancer screening

Pap smears and HPV testing have driven dramatic declines in cervical cancer mortality — roughly 70 percent since widespread screening began. Current USPSTF guidelines recommend Pap tests every 3 years for women ages 21 to 65, or Pap plus HPV co-testing every 5 years for those 30 to 65. Both carry A ratings. The intervals are longer than historical practice because the evidence shows that annual Pap smears produce more false positives and unnecessary procedures without improving cancer detection at the population level.

Depression screening

The USPSTF gives depression screening a B recommendation for the general adult population, including pregnant and postpartum women. Brief validated instruments like the PHQ-2 and PHQ-9 can be administered in minutes. The USPSTF notes that screening is most effective when connected to systems for follow-up care — a positive screen that goes unaddressed does not help anyone — but the evidence for benefit when care infrastructure is in place is solid.

Lipid disorders and statin consideration

For adults aged 40 to 75 who have no history of cardiovascular disease, the USPSTF recommends using cardiovascular risk calculators alongside lipid testing to assess 10-year risk, with statins recommended for those at elevated risk (B recommendation). A basic lipid panel is a low-cost, low-risk test that feeds into a broader risk conversation — not a standalone answer, but a useful data point.

Where the evidence is weaker — or the harms matter

The Choosing Wisely campaign, a physician-led initiative that has produced evidence-based lists of tests and procedures to question, is a useful complement to USPSTF guidance. Here are several areas where caution is warranted.

PSA testing for prostate cancer in average-risk men

Prostate-specific antigen (PSA) testing gets a C recommendation from the USPSTF for men ages 55 to 69, meaning the decision should be individualized. For average-risk men under 55 or over 70, it is D-rated. The reason is a well-documented pattern of over-diagnosis: PSA testing finds many slow-growing cancers that would never cause symptoms or death, leading to biopsies, anxiety, and sometimes aggressive treatments (surgery, radiation) with lasting side effects including incontinence and erectile dysfunction. The USPSTF is clear that this is a shared decision, not a blanket recommendation — men with family history or other elevated risk factors have a different calculation. But routine PSA screening as a default for every middle-aged man without a conversation about tradeoffs is not well-supported.

Full-body CT scans and executive health panels

Direct-to-consumer imaging centers market full-body CT scans as a comprehensive health check. The USPSTF, the American College of Radiology, and multiple physician societies do not recommend them for asymptomatic, average-risk adults. The reasons: incidental findings — anomalies unrelated to any disease — are extremely common on full-body CT, triggering cascades of follow-up imaging, biopsies, and procedures. The cumulative radiation dose also carries a small but nonzero cancer risk. Choosing Wisely specifically lists full-body CT as a test to avoid without specific clinical indication.

Cardiac calcium scoring and extended cardiac panels for low-risk individuals

Coronary artery calcium (CAC) scoring has legitimate uses in intermediate-risk patients where the cardiovascular risk calculation is genuinely uncertain — it is mentioned in some guidelines as a tiebreaker. As a routine test for low-risk individuals, however, it generates incidental findings and downstream testing without demonstrated mortality benefit at the population level. Similarly, panels marketed as comprehensive heart health checks — including highly sensitive inflammatory markers, advanced lipid subfractions, and genetic panels — are generally not backed by evidence that acting on them changes outcomes for low-risk people.

Life stage matters: a simplified map

Rather than an exhaustive table, here is a rough framework based on USPSTF A and B ratings:

  • All adults, every few years: Blood pressure, depression screening, cholesterol if not done recently
  • Adults 21–65 with a cervix: Cervical cancer screening per current intervals
  • Adults 45–75: Colorectal cancer screening (any validated modality)
  • Adults 50–80 with heavy smoking history (30 pack-years): Annual low-dose CT lung screening (A recommendation)
  • Women 40–74 (per individual discussion): Mammography every 1–2 years (B recommendation with note that benefits and harms should be discussed)
  • Adults with risk factors for prediabetes: Blood glucose/prediabetes screening starting at 35 (B recommendation)

Talking to your doctor — and your insurer

Two practical realities shape whether preventive care actually helps you.

First, generic checklists cannot substitute for a conversation about your personal risk. Family history, lifestyle, existing conditions, and prior test results all change the calculation. A physician who knows you can tell you whether the USPSTF’s population-level C recommendation applies to your specific situation differently. The framework here is shared decision-making: the clinician provides evidence and risk estimates; you provide your values and preferences about tradeoffs like false positives versus the reassurance of a negative test.

Second, the insurance and cost dimension is real. As noted above, A and B recommendations are covered without cost-sharing under the ACA for most private plans and Medicaid expansion programs. Medicare has its own preventive benefit schedule, which differs in some particulars. Before agreeing to a test that is not clearly A or B rated, it is worth asking two questions: Is this covered? And what happens if something incidental is found — what are the follow-up costs?

The KFF has documented that confusion about what is covered preventively leads many patients to avoid screenings they have no financial reason to avoid, and to pay out-of-pocket for tests with weak evidence. Neither outcome serves your health.

The bottom line

Preventive medicine at its best is targeted, evidence-based, and connected to follow-up care. At its worst, it is a source of anxiety, unnecessary procedures, and costs without commensurate benefit. The USPSTF grading system is the most rigorous public tool Americans have for distinguishing between the two.

The highest-yield things most adults can do are genuinely unglamorous: know your blood pressure, get colorectal cancer screening after 45, keep up with cervical cancer screening if applicable, and have a periodic conversation with a primary-care clinician about where you sit on the cardiovascular risk spectrum. These do not require expensive panels or boutique imaging. They require showing up.

This article summarizes publicly available clinical guidance for general informational purposes. It is not a substitute for personalized medical advice. Screening recommendations depend on individual health history, risk factors, and clinical judgment. Talk with your own clinician about what is appropriate for you.